News
How many years of aromatase inhibitor therapy in breast cancer?
- Author:
- Neil Osterweil
Postmenopausal women with hormone receptor–positive breast cancer may need only 2 years of additional endocrine therapy instead of 5, shows a new...
News
Good survival, outcomes with TARE for HCC in practice
- Author:
- Neil Osterweil
Transarterial radioembolization was successfully employed with good safety across 25 centers in eight European countries.
News
Testosterone replacement shows CV benefit in hypogonadal men
- Author:
- Neil Osterweil
Among men with hypogonadism who received testosterone replacement every 3 months, cardiovascular parameters were better and there were fewer...
News
Fibrosis severity in ALD predicts survival
- Author:
- Neil Osterweil
Having significant or advanced fibrosis puts patients with ALD at high risk of death or decompensation in the short term.
News
Protein expression may predict HBV DNA suppression
- Author:
- Neil Osterweil
Protein expression patterns after treatment for HBV infections may help clinicians refine therapy.
News
Rapid core antigen HCV tests could expand accessibility
- Author:
- Neil Osterweil
Low-cost rapid diagnostic testing for HCV plus lab RNA confirmation of negatives may improve access to treatment in countries with limited...
News
Novel liver dialysis device may safely curb ACLF
- Author:
- Neil Osterweil
The investigational DIALIVE liver dialysis system removes and replaces albumin and filters endotoxins in patients with acute-on-chronic liver...
News
Worse survival with recurrent AIH after transplant
- Author:
- Neil Osterweil
Patients with recurrent autoimmune hepatitis after transplant have a more than 10-fold greater risk for graft failure than those without...
News
Real-world CAR T outcomes for DLBCL mimic clinical trials
- Author:
- Neil Osterweil
Survival and safety outcomes in the monde réel (real world) were comparable with those seen in clinical trials for patients with advanced...
News
Ponatinib/blinatumomab start strong against Ph+ALL
- Author:
- Neil Osterweil
The combined agents were associated with high complete response and molecular remission rates as frontline...
News
HMAs benefit children with relapsed/refractory AML
- Author:
- Neil Osterweil
Azacitidine and decitabine alone or in combination may help children and young adults reach stem cell transplant...
News
Novel molecule prolongs half-life of bleeding disorder treatments
- Author:
- Neil Osterweil
In a perfect example of serendipity, an aptamer designed to prevent ischemic strokes actually results in...
News
CAR T cells rescue younger children with relapsed/refractory ALL
- Author:
- Neil Osterweil
Children younger than 3 years with relapsed/refractory acute lymphoblastic leukemia had CAR T therapy outcomes similar to those of older children...
News
Experimental antibody-drug conjugate shown active against r/r DLBCL
- Author:
- Neil Osterweil
The experimental antibody-drug conjugate naratuximab targets CD37, a surface marker on most B-cell lymphoma...
News
Promising HER2+/HR– breast cancer survival with de-escalated therapy
- Author:
- Neil Osterweil
Dual HER2 blockade and paclitaxel therapy was associated with excellent overall and invasive disease-free...